Systematic review: Methotrexate—A poorly understood and underused medication in inflammatory bowel disease
Alimentary Pharmacology & Therapeutics · 2024-09 · 60 (6) · 686-700
DOI: 10.1111/apt.18194 ↗At a glance
Systematische Übersicht in Alimentary Pharmacology & Therapeutics, published online on 2024-07-30. Written by Léa Sequier and 8 co-authors. Institution: Department of Gastroenterology and Hepatology, Nîmes University Hospital, Carémeau Hospital, Nîmes, France. Major MEDLINE topics: Immunosuppressive Agents, Methotrexate. Cited 24 times so far (Crossref); 114 references.
Abstract (original language)
Background
Methotrexate, an immunosuppressant used for the treatment of inflammatory bowel disease (IBD) for over 30 years, remains underused compared to thiopurines.
Aims
To review the efficacy, safety, optimal dosing and delivery regimens of methotrexate in adults with IBD.
Methods
We conducted a systematic review of studies involving patients with IBD treated with methotrexate from inception to August 2023. All studies were included from the MEDLINE database via PubMed.
Results
For Crohn's disease, we included eight randomised controlled trials (RCTs) and 17 observational studies. Parenteral methotrexate effectively increased remission rates in steroid‐dependent patients at 25 mg/week for 16 weeks and at 15 mg/week for maintenance. Methotrexate can be used in combination with anti‐tumour necrosis factor (TNF) agents to reduce immunogenicity. Data comparing thiopurines and methotrexate remain scarce. For ulcerative colitis (UC), we included five RCTs and 10 observational studies were included; there was no evidence to support the use of methotrexate in (UC). We extracted safety data from 17 studies; mild‐to‐moderate adverse effects were common. The incidence of liver fibrosis or cirrhosis was low.
Conclusion
Methotrexate is effective at inducing and maintaining remission in steroid‐refractory Crohn's disease and can reduce anti‐TNF‐induced immunogenicity when used in combination therapy. Data regarding tolerance and safety are reassuring. These findings challenge preconceived ideas on methotrexate and suggest that it is a valid first‐line conventional option for the treatment of mild‐to‐moderate Crohn's disease.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Gastroenterology and Hepatology, Nîmes University Hospital, Carémeau Hospital, Nîmes, France.
- Department of Gastroenterology and Hepatology A, Saint-Éloi Hospital, Montpellier, France.
- Department of Gastroenterology, Nancy University Hospital, Vandœuvre-lès-Nancy, France.
- INSERM, NGERE, University of Lorraine, Nancy, France.
- INFINY Institute, Nancy University Hospital, Vandœuvre-lès-Nancy, France.
- FHU-CURE, Nancy University Hospital, Vandœuvre-lès-Nancy, France.
ORCID profiles: Sailish Honap, Vipul Jairath, Silvio Danese, Laurent Peyrin-Biroulet
Cite
APA
Sequier, L., Caron, B., Loeuille, D., Honap, S., Jairath, V., Netter, P., Danese, S., Sibilia, J., & Peyrin-Biroulet, L. (2024). Systematic review: Methotrexate—A poorly understood and underused medication in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 60(6), 686-700. https://doi.org/10.1111/apt.18194
Vancouver
Sequier L, Caron B, Loeuille D, Honap S, Jairath V, Netter P, et al. Systematic review: Methotrexate—A poorly understood and underused medication in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 2024;60(6):686-700. doi:10.1111/apt.18194
BibTeX
@article{Sequier2024,
author = {Sequier, Léa and Caron, Bénédicte and Loeuille, Damien and Honap, Sailish and Jairath, Vipul and Netter, Patrick and Danese, Silvio and Sibilia, Jean and Peyrin-Biroulet, Laurent},
title = {Systematic review: Methotrexate—A poorly understood and underused medication in inflammatory bowel disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
volume = {60},
number = {6},
pages = {686--700},
doi = {10.1111/apt.18194}
}
EUVIMED